Clinical Trial Update: Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BRC-003 for refractory post-traumatic epilepsy has been withdrawn. The trial was sponsored by Dr. Paul Lyons.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Epilepsy

Drugs mentioned

• BRC-003

Snippet

Sponsor: Dr. Paul Lyons | Conditions: Post-traumatic Epilepsy | Phase 2 | Status: WITHDRAWN